CN113804892A - Application of urine fatty acid binding protein 4 and polypeptide fragment thereof in burn - Google Patents

Application of urine fatty acid binding protein 4 and polypeptide fragment thereof in burn Download PDF

Info

Publication number
CN113804892A
CN113804892A CN202010555483.7A CN202010555483A CN113804892A CN 113804892 A CN113804892 A CN 113804892A CN 202010555483 A CN202010555483 A CN 202010555483A CN 113804892 A CN113804892 A CN 113804892A
Authority
CN
China
Prior art keywords
binding protein
fatty acid
burn
urine
acid binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010555483.7A
Other languages
Chinese (zh)
Inventor
张曼
王佶图
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Shijitan Hospital
Original Assignee
Beijing Shijitan Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Shijitan Hospital filed Critical Beijing Shijitan Hospital
Priority to CN202010555483.7A priority Critical patent/CN113804892A/en
Publication of CN113804892A publication Critical patent/CN113804892A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/40—Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides an application of urine Fatty acid binding protein 4 (fat acid-binding protein 4) and polypeptide fragments thereof, in particular to an application of urine Fatty acid binding protein 4 and polypeptide fragments thereof in preparing preparations for burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like. The burn is an important common wound in daily life, about 5000-100000 people burn in every 100 million people every year, according to the statistics of the world health organization, more than 30 million people die of burn patients all year around the world, and the survival rate of the serious burn treatment is still at a lower level. The invention proves that the expression of urine fatty acid binding protein 4 and polypeptide fragments thereof is increased in burn patients compared with healthy people (normal control group). Can be used for various purposes of detecting burn patients. The invention exerts the advantages of noninvasive acquisition, large-scale repeated sampling and convenient storage of the urine specimen, and utilizes the urine specimen to detect the urine fatty acid binding protein 4 and the polypeptide fragment thereof.

Description

Application of urine fatty acid binding protein 4 and polypeptide fragment thereof in burn
Technical Field
The invention relates to a new application of urine fatty acid binding protein 4 and a polypeptide fragment thereof, in particular to an application of urine fatty acid binding protein 4 and a polypeptide fragment thereof in burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
Background
Burn refers to the injury of skin, tissue and even deep viscera of human body caused by chemical substances such as flame, high-temperature gas, scorching solid or liquid, radioactive rays, electric energy, strong acid and strong alkali, etc., and is a systemic comprehensive disease. After burn, a large amount of reactions such as necrosis, infection, shock, blood coagulation dysfunction and the like of wound tissues can cause a series of pathophysiological changes of organisms. Burns of different degrees have different influences on human bodies, serious burns can damage the environment in the human bodies, the burn patients have pathophysiological changes of complexity of various systems, and relevant detection indexes can correspondingly change along with the difference of the severity of the burns. Timely detection of changes in these indices can provide valuable reference for clinicians in many areas, such as disease diagnosis, disease judgment, treatment selection, and patient prognosis assessment.
However, patients with severe burns have poor skin integrity, and clinical use of hematological tests as invasive tests on the skin in such patients has presented difficulties, and repeated blood draw tests can also exacerbate patient pain. Urine as ultrafiltrate of blood contains abundant biological information, and the collection process has the advantages of non-invasive and convenient operation, and the like, which is particularly obvious in the detection of burn patients. The biomarker which is helpful for burn diagnosis and reflects disease change is searched in urine, so that the life quality and compliance of burn patients can be improved, the pain of blood collection for many times is relieved, and a reference basis which is favorable for disease diagnosis and treatment is better provided for clinicians.
Fatty acid binding protein 4 (FAtty acid-binding protein 4, FABP 4) is one of the members of the Fatty acid binding protein family and is a chaperone for Free Fatty Acids (FFA). FABP4 not only regulates adipocyte differentiation, but also is involved in sugar and fat metabolism in vivo. At present, researches prove that FABP4 is closely related to the occurrence of diseases such as insulin resistance, hyperglycemia and the like, and the level of peripheral blood FABP4 protein is considered as a biomarker of various diseases such as metabolic diseases, vascular diseases, obesity and the like. In the study, the expression of the fatty acid binding protein 4 in the urine of the burn patient is up-regulated compared with that of a healthy human group, and the content of the protein in the urine of the burn patient is increased.
Compared with the common clinical blood sample, the urine can be collected in a non-invasive, continuous and large amount; without homeostatic regulation, more various and larger changes can be accumulated, and many pathophysiological changes of the body can be reflected in urine. Some protein polypeptides with relatively small molecular weight, such as hormones and cytokines, are excreted into urine quickly after entering blood, and the probability that the proteins and polypeptides are detected in urine is much higher than that in blood; before urine is collected, a possible protein degradation process in urine is completed, so that urine protein can be kept stable for a longer time. In order to relieve the pain of multiple blood sampling of burn patients, the experiment is expected to realize the diagnosis and disease monitoring of the burn patients by painless, convenient, quick and easily repeated urine detection through the research of urine protein or polypeptide on the basis of the methodology exploration of the early stage, and also lays a foundation for the further research of the urine polypeptide detection kit.
Disclosure of Invention
The invention aims to provide application of urine fatty acid binding protein 4 and polypeptide fragments thereof in preparation of preparations for burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
Preferably, the amino acid sequence of the urine fatty acid binding protein 4 is shown in SEQ ID NO.1 (MCDAFVGTWK LVSSENFDDY MKEVGVGFAT RKVAGMAKPN MIISVNGDVI TIKSESTFKN TEISFILGQE FDEVTADDRK VKSTITLDGG VLVHVQKWDG KSTTIKRKRE DDKLVVECVM KGVTSTRVYE RA); or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1 and has the same function with the amino acid sequence shown in SEQ ID NO. 1.
Preferably, the preparation is a detection kit for the urine fatty acid binding protein 4 and polypeptide fragments thereof of the burn patient.
Preferably, the kit includes one or more of an immunization method for antigen-antibody reaction and kits thereof such as aptamer antibodies or antibody fragments capable of specifically binding to fatty acid binding protein 4 and polypeptide fragments thereof.
Preferably, the detection method comprises methods such as mass spectrometry for directly detecting the fatty acid binding protein 4 and the polypeptide fragment thereof and related kits thereof.
Preferably, the detection method comprises a related nucleic acid detection method for directly detecting the fatty acid binding protein 4 and the polypeptide fragment thereof and a related kit thereof.
Preferably, the kit further comprises a component selected from the group consisting of: the kit comprises a solid phase carrier, a diluent, a reference substance, a standard substance, a quality control substance, a detection antibody, a second antibody diluent, a luminescent reagent, a washing solution, a color development solution and a stop solution, wherein the solid phase carrier is any one or a combination of a plurality of the solid phase carrier, the diluent, the reference substance, the standard substance, the quality control substance, the detection antibody, the second antibody and the second antibody diluent.
Preferably, the standard comprises a fatty acid binding protein 4 standard, a humanized tag antibody standard; preferably, the quality control product comprises: a fatty acid binding protein 4 quality control product and a humanized label antibody quality control product; preferably, the solid support comprises: particles, microspheres, glass slides, test strips, plastic beads, liquid phase chips, micro-porous plates or affinity membranes and other carriers with the same functions.
Preferably, the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide and cellulose, and has similar functions.
The inventor firstly collects urine samples of healthy people and burn patients, centrifugates for 5min at 4000r/min, absorbs supernatant, measures the concentration of extracted protein by a Bradford method, and carries out SDS-PAGE enzymolysis. The Label-free mass spectrometry of the urine samples was performed by the OrbitrapFasion type mass spectrometer. And performing quantitative calculation on data obtained in the mass spectrum of the burn group and the normal control group. The differential polypeptide is screened by using the difference of protein expression amount more than 1.5 times and P <0.05 as a reference standard through statistical test. Then, the inventor identifies the differential polypeptide with statistical significance, and searches by using a database to obtain the differential protein fatty acid binding protein 4.
Compared with healthy people, the fatty acid binding protein 4 and the polypeptide fragment thereof are highly expressed in urine of burn patients and have better consistency with clinical diagnosis. Therefore, the urine fatty acid binding protein 4 and the polypeptide fragment thereof can be used for auxiliary diagnosis or disease monitoring of the burn.
The invention exerts the advantages of noninvasive acquisition, large-scale repeated sampling and convenient storage of the urine specimen, and utilizes the urine specimen to detect the urine fatty acid binding protein 4 and the polypeptide fragment thereof.
In order to make the aforementioned and other objects, features and advantages of the present invention comprehensible, preferred embodiments accompanied with figures are described in detail below.
Drawings
FIG. 1 is a graph showing the content of urine fatty acid binding protein 4 and its polypeptide fragments in burn and healthy control groups.
FIG. 2 is a schematic representation of the involvement of fatty acid binding protein 4 in major biological processes.
Detailed Description
Example 1Collection and processing of urine specimens
Burn patients were selected as the burn group, and contemporary physical examiners were selected as the normal control group. 30ml samples of fresh morning urine were collected from each group of subjects after admission, and those who failed to urinate normally collected their morning urine from their catheters and placed in dry, clean containers. Centrifuging the collected urine specimen at 4000r/min for 5min, sucking supernatant, subpackaging 2ml per tube, and storing in a refrigerator at-80 ℃.
Example 2Mass spectrometry and screening of urine polypeptides
Extracting protein from urine sample, and determining the concentration of extracted protein. Mass spectrometry of urine samples was performed by orbitrapfuision type mass spectrometry. And performing quantitative calculation on data obtained in the mass spectrum of the experimental group and the normal control group. The comparison among groups adopts t-test to carry out differential analysis, and differential expression proteins are screened by using the difference of protein expression quantity more than 1.5 times and taking the statistical test that P <0.05 as a reference standard.
Example 3Identification and analysis of differential Polypeptides
The used database is a Unit _ Homo database, the generated mass spectrum original file is processed by MaxQuant software, and the retrieval parameter setting is shown in Table 1.
Figure DEST_PATH_IMAGE001
Compared with healthy people, the fatty acid binding protein 4 is highly expressed in urine of burn patients as shown in figure 1, the main biological processes involved in the urine are shown in figure 2, and the expression of the fatty acid binding protein 4 in urine of normal control groups and burn groups is significantly different.
Although the present invention has been described with respect to the preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
SEQUENCE LISTING
<110> Beijing century bed Hospital affiliated to capital medical university
<120> application of urine fatty acid binding protein 4 and polypeptide fragment thereof in burn
<130> 1
<140> 20PFABP4
<141> 2020-05-10
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 132
<212> PRT
<213> Human Urine
<400> 1
Met Cys Asp Ala Phe Val Gly Thr Trp Lys Leu Val Ser Ser Glu Asn
1 5 10 15
Phe Asp Asp Tyr Met Lys Glu Val Gly Val Gly Phe Ala Thr Arg Lys
20 25 30
Val Ala Gly Met Ala Lys Pro Asn Met Ile Ile Ser Val Asn Gly Asp
35 40 45
Val Ile Thr Ile Lys Ser Glu Ser Thr Phe Lys Asn Thr Glu Ile Ser
50 55 60
Phe Ile Leu Gly Gln Glu Phe Asp Glu Val Thr Ala Asp Asp Arg Lys
65 70 75 80
Val Lys Ser Thr Ile Thr Leu Asp Gly Gly Val Leu Val His Val Gln
85 90 95
Lys Trp Asp Gly Lys Ser Thr Thr Ile Lys Arg Lys Arg Glu Asp Asp
100 105 110
Lys Leu Val Val Glu Cys Val Met Lys Gly Val Thr Ser Thr Arg Val
115 120 125
Tyr Glu Arg Ala
130

Claims (9)

1. The urine fatty acid binding protein 4 and the polypeptide fragment thereof are applied to the preparation of preparations for burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
2. The use of claim 1, wherein the amino acid sequence of urinary fatty acid binding protein 4 is as shown in SEQ ID No. 1; or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1 and has the same function with the amino acid sequence shown in SEQ ID NO. 1.
3. The use of claim 1, wherein the preparation is a kit for detecting fatty acid binding protein 4 and polypeptide fragments thereof in urine of burn patients.
4. Use according to claim 3, wherein the kit comprises one or more of an immunization method for antigen-antibody reaction and kits thereof such as aptamer antibodies or antibody fragments capable of specifically binding to fatty acid binding protein 4 and polypeptide fragments thereof.
5. The use of claim 3, wherein the detection method comprises mass spectrometry and related kits for directly detecting fatty acid binding protein 4 and its polypeptide fragments.
6. The use of claim 3, wherein the detection method comprises a method for directly detecting fatty acid binding protein 4 and polypeptide fragments thereof or nucleic acid related thereto, and a kit related thereto.
7. The use according to claim 3, wherein the kit further comprises a component selected from the group consisting of: the kit comprises a solid phase carrier, a diluent, a reference substance, a standard substance, a quality control substance, a detection antibody, a second antibody diluent, a luminescent reagent, a washing solution, a color development solution and a stop solution, wherein the solid phase carrier is any one or a combination of a plurality of the solid phase carrier, the diluent, the reference substance, the standard substance, the quality control substance, the detection antibody, the second antibody and the second antibody diluent.
8. The use of claim 7, wherein the standard comprises a fatty acid binding protein 4 standard, a humanized tag antibody standard; preferably, the quality control product comprises: a fatty acid binding protein 4 control product and a humanized label antibody quality control product; preferably, the solid support comprises: particles, microspheres, glass slides, test strips, plastic beads, liquid phase chips, micro-porous plates or affinity membranes and other carriers with the same functions.
9. The use of claim 8, wherein the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide, cellulose, and carriers with similar functions.
CN202010555483.7A 2020-06-17 2020-06-17 Application of urine fatty acid binding protein 4 and polypeptide fragment thereof in burn Pending CN113804892A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010555483.7A CN113804892A (en) 2020-06-17 2020-06-17 Application of urine fatty acid binding protein 4 and polypeptide fragment thereof in burn

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010555483.7A CN113804892A (en) 2020-06-17 2020-06-17 Application of urine fatty acid binding protein 4 and polypeptide fragment thereof in burn

Publications (1)

Publication Number Publication Date
CN113804892A true CN113804892A (en) 2021-12-17

Family

ID=78943555

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010555483.7A Pending CN113804892A (en) 2020-06-17 2020-06-17 Application of urine fatty acid binding protein 4 and polypeptide fragment thereof in burn

Country Status (1)

Country Link
CN (1) CN113804892A (en)

Similar Documents

Publication Publication Date Title
CN113777314A (en) Application of urine ankle protein 1 and polypeptide fragment thereof in burn
CN113804892A (en) Application of urine fatty acid binding protein 4 and polypeptide fragment thereof in burn
CN113804893A (en) Application of urine type I collagen alpha 1 chain and polypeptide fragment thereof in burn
CN113804894A (en) Application of urine tumor necrosis factor receptor superfamily member 19L and polypeptide fragment thereof in burn
CN113804890A (en) Application of urine programmed cell death 6 interaction protein and polypeptide fragment thereof in burn
CN113777302A (en) Application of urine complement factor D and polypeptide fragment thereof in burn
CN113804891A (en) Application of urine C-reactive protein and polypeptide fragment thereof in burn
CN113777305A (en) Application of urine monoadenosine diphosphate ribosyltransferase and polypeptide fragment thereof in burn
CN113804889A (en) Application of urine XII type collagen alpha 1 chain and polypeptide fragment thereof in burn
CN113777315A (en) Application of uroubiquitin-like protein ISG15 and polypeptide fragment thereof in burn
CN113804895A (en) Application of urine immunoglobulin heavy chain variable region 3-7 and polypeptide fragment thereof in burn
CN113777317A (en) Application of urine major vault protein and polypeptide fragment thereof in burn
CN113820485A (en) Urine carbonic anhydrase 3 and application of polypeptide fragment thereof in burn
CN113777316A (en) Application of urine C4b binding protein alpha chain and polypeptide fragment thereof in burn
CN113759125A (en) Urinary uteroglobin and application of polypeptide fragments thereof in burn
CN113759123A (en) Application of urine cartilage intermediate layer protein and polypeptide fragment thereof in burn
CN113777306A (en) Urine fructose diphosphate aldolase B and application of polypeptide fragment thereof in burn
CN114113580A (en) Application of urine thrombomodulin and polypeptide fragment thereof in burn
CN113777313A (en) Application of urine vitamin K-dependent protein S and polypeptide fragment thereof in burn
CN114252606A (en) Application of urine cysteine dioxygenase-1 and polypeptide fragment thereof in allergic diseases
CN113759133A (en) Application of urinary angiotensinogen and polypeptide fragment thereof in burn
CN114113622A (en) Urine guanine nucleotide binding protein G(s) subunit alpha short subtype and application of polypeptide fragment thereof in burn
CN114252628A (en) Application of urine regeneration protein and polypeptide fragment thereof in allergic diseases
CN113759122A (en) Application of urine protein Z and polypeptide fragment thereof in burn
CN113777304A (en) Application of urine plasminogen and polypeptide fragment thereof in burn

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination